tiprankstipranks
Zelira Therapeutics Advances in FDA Trials and Product Development
Company Announcements

Zelira Therapeutics Advances in FDA Trials and Product Development

Zelira Therapeutics (AU:ZLD) has released an update.

Don't Miss our Black Friday Offers:

Zelira Therapeutics has made significant strides in its HOPE® program, receiving positive feedback from the FDA to advance towards IND submission and clinical trials. The company is also on track to transform Zenivol® into a capsule formulation by early 2025, enhancing its product offerings in cannabinoid medicines. These developments position Zelira as a key player in the pharmaceutical market, particularly in treating irritability in Phelan McDermid Syndrome comorbid with Autism Spectrum Disorder.

For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Unveils Growth Plans at Investment Conference
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Secures Shareholder Support at AGM
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Prepares for 2024 Shareholders Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App